Clinical Takeaway
Clinical research now categorizes cannabis-based products by their THC-to-CBD ratio, source, and delivery method, allowing for more precise comparisons across trials. This updated systematic review draws on randomized placebo-controlled trials through mid-2025 to assess both benefits and harms of cannabinoids in chronic pain populations. Patients and clinicians should look to this evolving evidence base when weighing cannabinoid options, recognizing that product formulation and administration route matter for outcomes.
#1 Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Citation: Chou Roger et al.. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.. Annals of internal medicine. 2026. PMID: 41429020.
Design: 5 Journal: 3 N: 4 Recency: 3 Pop: 2 Human: 1 Risk: -2
This systematic review addresses a critical evidence gap by synthesizing randomized controlled trial data on cannabinoid efficacy and safety for chronic pain management, where clinical guidance remains limited despite increasing patient demand and regulatory approval of cannabis-based products. The THC-to-CBD ratio categorization provides clinically relevant stratification for understanding differential therapeutic effects and adverse event profiles, enabling more informed prescribing decisions for patients with inadequate response to conventional analgesics.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: 25 short-term (1 to 6 months) randomized controlled trials (n = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S
🧠 This updated systematic review reinforces what many cannabis medicine practitioners already recognize: the evidence for cannabinoids in chronic pain remains heterogeneous and modest at best, with meaningful gaps between patient expectations and what rigorous trials actually demonstrate. The authors’ stratification by THC-to-CBD ratio is clinically useful, as the pharmacodynamic effects and side effect profiles differ substantially across product types, yet most primary care providers still lack clear guidance on which ratios might benefit specific pain conditions. Key confounders limiting the evidence base include highly variable study populations, inconsistent dosing protocols, short follow-up periods, and the persistent difficulty of blinding in cannabis trials, all of which complicate our ability to make definitive recommendations. Rather than viewing this as a negative, clinicians should recognize it as an opportunity to engage patients in shared decision-making conversations that acknowledge both the preliminary promise of cannabinoids and the legitimate uncertainties, while emphasizing that conventional pain management strategies and psychosocial interventions remain the evidence foundation upon which any cannabinoid